As of August 2026, the biggest teen-acne change is the U.S. approval of Differin Epiduo Acne Gel for nonprescription use from age 12. It expands access to a recommended drug combination, while UK prescribing rules have changed and a new treatment has entered late-stage testing.
These developments affect different groups and should not be treated as interchangeable. The U.S. change covers self-treatment, the UK update concerns closely supervised isotretinoin, and the clinical trial does not make its drug available.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed for U.S. teens?
- How should the new OTC gel be used?
- Do benzene findings make benzoyl peroxide unsafe?
- What changed for prescription treatment in the UK and EU?
- What should readers watch next?
What changed for U.S. teens?
On May 22, the FDA approved Differin Epiduo acne Gel—adapalene 0.1% plus benzoyl peroxide 2.5%—for nonprescription treatment in adults and children aged 12 and older. The switch makes this specific two-drug formulation available without a prescription to eligible U.S. teens, according to the FDA's prescription-to-nonprescription switch list.
That matters because acne affects about 85% of adolescents. The American Academy of Dermatology strongly recommends benzoyl peroxide, topical retinoids such as adapalene, and combinations of those treatments. The practical gain is convenience: one OTC product now combines two recommended treatment types. However, the approval applies only to people 12 and older and does not turn every acne treatment into an appropriate self-care option.
How should the new OTC gel be used?
The FDA-approved label directs users to apply a thin layer once daily across the entire affected area. That means following the labeled area-based approach, rather than applying a large amount only to individual blemishes.
Before starting, check the label's main boundaries: Nonprescription status removes the prescription requirement, not the need to follow safety directions. These instructions appear in the FDA-approved Differin Epiduo label.
- The user must be at least 12 years old.
- The gel should not be applied to damaged skin.
- Anyone pregnant or breastfeeding should consult a health professional before use.
Do benzene findings make benzoyl peroxide unsafe?
FDA testing in 2025 found elevated benzene in six of 95 tested benzoyl-peroxide acne products, leading to limited retail recalls. More than 90% of the products had undetectable or extremely low benzene levels, and the agency judged the cancer risk from decades of daily use to be very low, as explained in the FDA's benzene testing update.
Those results do not support treating every benzoyl-peroxide product as equally affected. They show why readers should distinguish a product-specific recall from a warning about an entire treatment category.
What changed for prescription treatment in the UK and EU?
From January 22, 2026, UK patients under 18 no longer need approval from a second prescriber before starting isotretinoin. The revised rules retain risk acknowledgement, pre-treatment information, monitoring, and future audits, according to the UK MHRA's prescribing update. This may reduce delays for teens at risk of scarring from severe acne.
It does not broaden isotretinoin to routine cases: the medicine remains for severe disease that has not responded to other treatments, with prescribers responsible for managing its risks. In the EU, clascoterone, a topical anti-androgen sold as Winlevi, was authorized in October 2025 for facial acne in adolescents aged 12–17. Adolescent treatment is limited to the face and restricted by dose because of a theoretical concern about systemic hormonal suppression. It remains a prescription product, not an OTC alternative to Differin Epiduo.
What should readers watch next?
Denifanstat is the main investigational development to follow. Sagimet Biosciences said in August 2026 that the FDA cleared its investigational new drug application for a U.S.
Phase 3 trial involving about 800 people aged 12 and older with moderate-to-severe acne, including roughly 450 adolescents. That clearance permits the study to proceed; it does not establish that denifanstat works or authorize its sale. The next meaningful evidence will come from the trial's results and any later regulatory review, so teens should not treat it as a currently available option.